Supra-Blan 2 t score as a multisystem-based risk score to predict poor 3-month outcome in acute ischemic stroke patients with intravenous thrombolysis

• Published in: CNS neuroscience & therapeutics Vol. 30; no. 2; p. e14381
• Main Authors: Jin, Huijuan, Peng, Qiwei, Li, Min, Sun, Shuai, Zhou, Jinghua, Hu, Jichuan, Huang, Ming, Chen, Xinglong, Li, Yanan, Zhou, Yifan, Wan, Yan, Hong, Candong, Chen, Shengcai, Hu, Bo
• Format: Journal Article
• Language: English
• Published: England 01.02.2024
• Subjects: Brain Ischemia - diagnostic imaging; Brain Ischemia - drug therapy; Fibrinolytic Agents - therapeutic use; Humans; Ischemic Stroke - diagnostic imaging; Ischemic Stroke - drug therapy; Retrospective Studies; Risk Factors; Stroke - diagnostic imaging; Stroke - drug therapy; Thrombolytic Therapy; Treatment Outcome; thrombolysis; prediction score; acute ischemic stroke; remote organ; outcome
• ISSN: 1755-5930; 1755-5949
• DOI: 10.1111/cns.14381

To develop and validate a novel weighted score integrating multisystem laboratory and clinical variables to predict poor 3-month outcome (mRS score of 3-6) in acute ischemic stroke (AIS) patients with intravenous thrombolysis (IVT) therapy. We retrospectively analyzed data from Trial of Revascularization Treatment for Acute Ischemic Stroke study. The Supra-Blan t score was derived using the data on age, the National Institutes of Health Stroke Scale score, history of atrial fibrillation, blood sugar level, neutrophil count, direct bilirubin level, platelet-lymphocyte ratio, and TnI level in the derivation cohort of 433 patients, and validated in a cohort of 525 patients. Furthermore, we compared the performance of the Supra-Blan t score with DRAGON, TURN, and SPAN-100 scores. The discrimination capacity in the derivation and validation cohorts was good for poor 3-month outcome (the area under the curve was 0.821 and 0.843, respectively). The cumulative incidence of poor 3-month outcome significantly increased across risk categories in the derivation (low-risk, 9.2%; medium-risk, 17.4%; and high-risk, 58.8%) and validation cohorts (12.7%, 36.5%, and 73.6%, respectively). The performance of the Supra-Blan t score was similar to or superior to DRAGON, TURN, and SPAN-100 scores. The Supra-Blan t score, based on easily available multisystem laboratory and clinical variables, reliably predicted poor 3-month functional outcome in AIS patients treated with IVT therapy featuring good calibration and discrimination.